Edition:
United States

BioScrip Inc (BIOS.O)

BIOS.O on Nasdaq

2.22USD
17 Nov 2017
Change (% chg)

$-0.05 (-2.20%)
Prev Close
$2.27
Open
$2.25
Day's High
$2.35
Day's Low
$2.21
Volume
478,175
Avg. Vol
1,294,718
52-wk High
$3.39
52-wk Low
$0.98

Latest Key Developments (Source: Significant Developments)

Bioscrip reports qtrly ‍loss per share $0.12​
Thursday, 2 Nov 2017 08:00am EDT 

Nov 2 (Reuters) - Bioscrip Inc :Bioscrip reports third quarter 2017 financial results.Q3 revenue $198.7 million versus I/B/E/S view $200.9 million.Sees FY 2017 revenue $805 million to $810 million.Bioscrip Inc says ‍updated its adjusted EBITDA guidance to a range of $42.0 million to $44.0 million for full-year 2017​.Bioscrip Inc - Qtrly ‍loss per share $0.12​.Bioscrip Inc sees FY 2017 ‍loss per share in range of $0.58 to $0.64.FY2017 earnings per share view $-0.55, revenue view $824.5 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.  Full Article

BioScrip can now dispense & administer radicava treatment option for amyotrophic lateral sclerosis
Thursday, 5 Oct 2017 08:00am EDT 

Oct 5 (Reuters) - Bioscrip Inc :BioScrip says can now dispense & administer Radicava (edaravone) treatment option for amyotrophic lateral sclerosis approved by U.S. FDA.  Full Article

Coliseum Capital reports 14.6 pct stake in Bioscrip
Friday, 8 Sep 2017 06:26am EDT 

Sept 8 (Reuters) - Bioscrip Inc :Coliseum Capital Management LLC reports 14.6 percent stake in Bioscrip Inc as of September 7, 2017 - SEC filing‍​.Coliseum Capital Management LLC earlier reported 16.5 percent stake in Bioscrip Inc as of August 17, 2017 - SEC filing‍​.  Full Article

U.S. files lawsuit against US Bioservices related to kickbacks, Novartis' Exjade
Tuesday, 22 Aug 2017 09:19am EDT 

Aug 22 (Reuters) - U.S. SAYS U.S. BIOSERVICES ARRANGED TO RECEIVE MORE PATIENT REFERRALS AND RELATED BENEFITS IN RETURN FOR ACHIEVING HIGHER PRESCRIPTION REFILL RATE FOR EXJADE:.  Full Article

BioScrip qtrly loss per share $0.26
Tuesday, 8 Aug 2017 08:00am EDT 

Aug 8 (Reuters) - BioScrip Inc :BioScrip reports second quarter 2017 financial results.Q2 revenue $218.1 million versus I/B/E/S view $220.2 million.Sees FY 2017 revenue $815 million to $835 million.Qtrly loss per share $0.26.Q2 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.BioScrip Inc - is reiterating its prior guidance of adjusted ebitda in range of $45.0 million to $55.0 million for full-year 2017..BioScrip Inc - company expects to incur restructuring expenses in a range of $11.0 million to $12.0 million in 2017.FY 2017 revenue view $865.9 million -- Thomson Reuters I/B/E/S.  Full Article

Ares Management reports 9.2 pct stake in Bioscrip
Monday, 10 Jul 2017 07:04am EDT 

July 10 (Reuters) - Ares Management::Ares Management reports 9.2 pct stake in Bioscrip as of June 29 - SEC filing.Ares Management says the shares of Bioscrip Inc were acquired, and are currently held, for investment purposes.Ares Management - pursuant to agreement, Ares shall have right to appoint one non-voting board observer for so long as Ares holds debt of co of at least $50 million.  Full Article

BioScrip announces new senior note facilities
Thursday, 29 Jun 2017 08:30am EDT 

June 29 (Reuters) - BioScrip Inc ::BioScrip announces new senior note facilities.BioScrip Inc - under agreement, company entered into a $200 million first lien note facility and a $110 million second lien note facility.BioScrip Inc - to use proceeds of facilities to repay in full all amounts outstanding under its previous senior credit facilities and its priming credit agreement.BioScrip Inc - also as part of agreement, will receive a $16 million common stock investment, and will issue common stock warrants with a 10-year term..  Full Article

Bioscrip provides update on Unitedhealthcare contract
Tuesday, 30 May 2017 08:00am EDT 

May 30 (Reuters) - Bioscrip Inc :Bioscrip provides update on Unitedhealthcare contract.Bioscrip Inc - ‍reached an agreement to continue to provide certain core product lines to unitedhealthcare beyond September 30, 2017​.Bioscrip Inc says company is reiterating its prior guidance for adjusted EBITDA in range of $45.0 million to $55.0 million for full-year 2017.Bioscrip Inc - ‍with agreement, Bioscrip will retain approximately $35 million of annualized profitable core revenue​.  Full Article

Bioscrip reports first quarter 2017 financial results
Thursday, 4 May 2017 08:00am EDT 

May 4 (Reuters) - Bioscrip Inc : :Bioscrip reports first quarter 2017 financial results.Q1 revenue $217.8 million versus I/B/E/S view $229.7 million.Bioscrip Inc - reiterating its prior guidance of adjusted EBITDA in range of $45.0 million to $55.0 million for full-year 2017.Bioscrip Inc - qtrly loss per common share $0.18.Q1 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $-0.36, revenue view $894.1 million -- Thomson Reuters I/B/E/S.  Full Article

BioScrip announces CFO transition
Thursday, 20 Apr 2017 09:00am EDT 

April 20 (Reuters) - BioScrip Inc :BioScrip announces CFO transition.BioScrip Inc says appointment of Stephen M. Deitsch to positions of senior Vice President, Chief Financial Officer and treasurer, effective April 24, 2017.BioScrip Inc says Deitsch succeeds Jeffrey Kreger, who stepped down from his roles as senior Vice President, Chief Financial Officer and treasurer.BioScrip Inc says reiterate our 2017 adjusted EBITDA forecast of $45 million to $55 million.  Full Article

BRIEF-BioScrip can now dispense & administer radicava treatment option for amyotrophic lateral sclerosis

* BioScrip says can now dispense & administer Radicava (edaravone) treatment option for amyotrophic lateral sclerosis approved by U.S. FDA Source text for Eikon: Further company coverage: